| |
|
|
|
|
|
|
|||
|
Blood, 1 December 2006, Vol. 108, No. 12, pp. 3700-3706. Prepublished online as a Blood First Edition Paper on August 24, 2006; DOI 10.1182/blood-2006-03-011973.
HEMATOPOIESIS
Wogonin sensitizes resistant malignant cells to TNF
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract |
|---|
|
|
|---|
has previously been used in anticancer therapy. However, the therapeutic application of TNF
was largely limited due to its general toxicity and the fact that it activates the NF-
Bfamily transcription factors, which are proinflammatory and antiapoptotic. To overcome this problem in vitro, specific NF-
B inhibitors or transcription or protein synthesis inhibitors such as actinomycin D and cycloheximide are usually used in combination to increase TNF
killing of tumor cells. However, these agents also cause harmful side effects in vivo. We show here that wogonin, derived from the popular Chinese herb Huang-Qin, attenuates NF-
B activity by shifting TNF
-induced free radical ·O2 to a more reduced nonradical product, H2O2, and thereby sensitizes TNF
-resistant leukemia cells to TNF
-induced apoptosis. Importantly, wogonin does not affect the viability of normal peripheral blood T cells. Wogonin also sensitizes TRAIL-induced apoptosis. Our data suggest a potential use of wogonin as a TNF
or TRAIL adjuvant for cancer treatment. Our data also demonstrate how a herbal compound enhances killing of tumor cells with reduced side effects compared with other treatments. | Introduction |
|---|
|
|
|---|
) was isolated in 1985 as the first mammalian protein with cytotoxicity to tumor cells and that induced tumor regression in mice.1 It is now known that TNF signaling may either induce cellular activation, apoptosis, or necrosis.2 TNF
was thought to be a potent anticancer agent due to its cytotoxicity against a number of tumor cell lines. However, the clinical use of TNF
is limited because of its systemic toxicity largely due to activation of the proinflammatory NF-
Bfamily transcription factors.3-5 NF-
B, apart from its proinflammatory activity, is also a negative regulator that antagonizes TNF
-induced killing.4,6 Clinically, the only success in TNF
therapy has occurred with isolated limb perfusion for a limited subset of susceptible tumors, such as melanoma and sarcoma.7 In general, TNF
is considered a key inducer of proinflammatory genes, and its primary role is to stimulate innate inflammatory responses to fight infections, whereas the function of its proapoptotic capability remains mysterious.8
Apoptosis involves 2 main pathways: the extrinsic pathway, which is initiated by binding of ligands to specific death receptors on the cell surface, and the intrinsic pathway, which is initiated at the mitochondria. TNF
is an inducer of the extrinsic pathway. In mammalians, TNF
signals through 2 distinct receptors, TNF receptor 1 (TNF-R1), the primary receptor for soluble TNF
, and TNF-R2, the main receptor for membrane-associated TNF
.5,9 The TNF-R1 signaling pathway can either trigger activation of NF-
Bcrucial for TNF
-mediated immunity, inflammation, and proliferationor activation of apical caspases as well as the c-JunN-terminal kinase (JNK) cascade, which leads to programmed cell death.2 TNF-R1 signaling can be divided into 2 distinct stages that sequentially activate NF-
B and apical caspases. Within a few minutes after binding of TNF
to TNF-R1 (stage 1), a signaling complex containing the receptor itself and the adaptor proteins TRADD, TRAF2, and RIP1 but lacking the FAS/APO-1associated death domain adaptor protein FADD forms and transduces signals that lead to activation of NF-
B and the JNK cascade.2,10,11 At later time points (stage 2), possibly after receptor internalization, RIP1, TRAF2, and TRADD dissociate from the receptor and recruit FADD and caspase-8 to form the second complex, which signals programmed cell death.2 Because of the long delay in the second complex assembly, NF-
B, activated at stage 1, has sufficient time to activate a variety of antiapoptotic factors, including members of the Bcl-2 family (Bcl-2, Bcl-xL), caspase inhibitors (FLIP, c-IAPs), and inhibitors of JNK activation (XIAP, GADD45
),4,5,12-14 which block the apoptotic pathway. Thus, in most instances, TNF-R1 signaling induces apoptosis only when NF-
B signaling is blocked.4,8,15
In recent years, traditional Chinese herbal remedies have gradually gained considerable attention as a new source of anticancer drugs as well as new chemotherapy adjuvants to enhance the efficacy of chemotherapy and to ameliorate the side effects of cancer chemotherapy. Although the healing mechanisms are still largely unknown, some of the drugs have been used to help cancer patients to fight their disease with reduced side effects compared with other treatments.16 Huang-Qin (Scutellaria baicalensis Georgi) is one of the most popular herbal remedies in China and several other Asian countries. The extracts from Huang-Qin have been widely used for clinical treatment of hyperlipemia, atherosclerosis, hypertension, dysentery, the common cold, and inflammatory diseases such as atopic dermatitis. One of the active components of Huang-Qin is 5,7-dihydroxy-8-methoxyflavone, also called wogonin. Wogonin is a flavonoid and has been shown to exert antioxidant,17 antiviral,18 antithrombotic,19 and anti-inflammatory activities. The antiinflammatory activity of wogonin is at least in part due to its ability to suppress expression of monocyte chemotactic protein-1, a crucial factor for early inflammatory responses.20 Wogonin also suppresses several inflammation-associated genes such as inducible nitric oxide synthase, cyclooxygenases, and lipoxygenases and, consequently, inhibits production of nitric oxide (NO) and prostaglandin E2.21-28 Wogonin has also been shown to exert cytostatic activities in several cancer cell lines, including bladder tumors,29 hepatocellular carcinoma,30 and myelogenous leukemia.31 Importantly, wogonin lacks toxicity for normal peripheral blood mononuclear cells.32
In this study, we show that wogonin can sensitize TNF
-resistant leukemia cells to TNF
-induced apoptosis. Wogonin directly shifts TNF
-induced free radical ·O2 to a more reduced state and thereby down-regulates TNF
-induced NF-
B activity. Besides TNF
, the tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) has been shown to kill various tumor cell lines in vitro and in vivo without being toxic to mice and nonhuman primates.33,34 However, 50% of tumor cell lines were TRAIL resistant.34 To overcome the resistance, combinations of TRAIL and chemotherapeutic drugs have been used to increase antitumor activity. In this study, we also show that wogonin can sensitize tumor cells to TRAIL-induced cell death.
| Materials and methods |
|---|
|
|
|---|
The malignant T-cell line CEM was cultured in RPMI 1640 medium (GIBCO, Grand Island, NY) supplemented with 10% FCS, 50 µg/mL gentamicin (GIBCO), 6 mM HEPES (GIBCO; 1 M solution), and 2 mM L-glutamine (GIBCO; 200 mM solution) at 37°C and 5% CO2. The Jurkat T-cell clone 16 (J16) and Jurkat T cells bearing an integrated NF-
Bdependent luciferase reporter (J-Luc-
B) (kindly provided by Thomas Wirth, Department of Physiological Chemistry, Ulm University, Germany) were cultivated in DMEM, 10% FCS, and 50 µM
-mercaptoethanol. Primary acute myeloid leukemia (AML) cells were obtained from bone marrow aspirates of AML patients (detailed information about this patient will be provided upon request) by Ficoll gradient and cultured in RPMI medium supplemented with 10% FCS, 2 mM L-glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin.
Preparation of human T cells from peripheral blood
Human peripheral T cells were prepared as described previously35 and were more than 90% CD3+. For activation, resting T cells (day 0) were cultured at 2 x 106/mL with 1 µg/mL PHA for 16 hours (day 1). Day 1 T cells were then washed 3 times and cultured for an additional 5 days in the presence of 25 U/mL IL-2 (day 6).
Redox measurement
TNF
-(100 ng/mL) or wogonin-(1 to 20 µM) treated cells were stained for 30 minutes with 5 µM of the H2O2-sensitive fluoresent dye dichlorofluorescein diacetate (DCFDA, FL-1) or 5 µM of the ·O2-sensitive dye dihydroethidium (DHE, FL-2) (Molecular Probes, Eugene, OR) at 37°C in the dark, washed 3 times with PBS, and subsequently assayed by FACScan (BD Biosciences, Heidelberg, Germany).
Determination of apoptosis
Cells were plated in triplicate and treated with wogonin (Wako Pure Chemical Industries, Osaka, Japan) in combination with either TNF
(purchased from Sigma, Taufkirchen, Germany) or LZ-TRAIL and His-TRAIL36 for the indicated periods of time at 37°C. Apoptotic cell death was examined by a forward scatter/side scatter (FSC/SSC) index of apoptotic-like change in cell size and granularity by FACScan37 or by analysis of DNA fragmentation according to the method of Nicoletti.38
Luciferase assay
The Jurkat T cells bearing J-Luc-
B were treated with TNF
in the presence or absence of wogonin. After 8 hours of treatment, cells were collected and lysed in passive lysis buffer (Promega, Heidelberg, Germany). Luciferase activity was determined in 10 µL of cell lysates using the luciferase assay substrate (Promega) with a Duolumat LB9507 luminometer (Berthold, Bad Wildbad, Germany).
| Results |
|---|
|
|
|---|
- and TRAIL-induced apoptosis
TNF
is toxic for a number of tumors; however, it also induces a profound inflammatory response through activation of NF-
B. Many tumor cells are resistant to TNF
largely due to NF-
B activation.12,14,15 Recently, we have found that wogonin can induce apoptotic cell death through the mitochondrial pathway in different malignant T-cell lines (M.L.-W., unpublished data, May 2006). Therefore, we asked whether wogonin could cooperate with the extrinsic (the receptor-mediated) pathway, such as the TNF
signaling pathway, to enhance killing of tumor cells. To address this question, malignant T-cell lines, the T-cell leukemia cell lines CEM and Jurkat bearing J-Luc-
B, were used as a test system to monitor apoptosis and NF-
B activity induced by TNF
and wogonin. Treatment of CEM and Jurkat cells with wogonin alone resulted in apoptotic cell death in a dose-dependent manner determined by both FSC/SSC and by DNA fragmentation (Figure 1A-C). At the concentration of 10 to 50 ng/mL, CEM and Jurkat T cells are resistant to TNF
-induced cell death (Figure 1A-C). However, treatment of these cells with a combination of TNF
and wogonin resulted in a synergistic (not only additive) increase in TNF
-induced cell death (Figure 1A-C). Thus, wogonin can sensitize TNF
-resistant cells to TNF
-induced apoptotic cell death.
To investigate whether wogonin can also sensitize other TNF-related ligands (eg, TRAIL-mediated cell death), we carried out experiments with a combination of wogonin and TRAIL. Similar to the combination of TNF
and wogonin, wogonin significantly enhanced TRAIL-induced apoptosis in 2 different Jurkat cell lines tested (Figure 1D). Treatment with 100 µM wogonin alone or with 10 to 20 ng/mL TRAIL alone resulted in 10% to 20% apoptotic cell death. However, in the combination of TRAIL and wogonin, 70% to 80% of cells underwent apoptosis. The experiments demonstrate that wogonin can also sensitize TRAIL-mediated apoptosis. To further investigate whether wogonin can enhance receptor-mediated apoptosis in primary tumor cells, AML cells freshly isolated from AML patients were subjected to the combination treatment. The AML cells were relatively resistant to TRAIL (approximately 4% cell death) and even showed less death when treated with TNF
. Treatment of the cells with the combination of wogonin either with TNF
or with TRAIL resulted in 8% to 15% and 9% to 28% death in 24 hours, respectively (Figure 1E). Thus, wogonin can sensitize TNF
- and TRAIL-resistant cells to TNF
- and TRAIL-induced cell death.
Wogonin neutralizes TNF
-induced free radical ·O2
It is well known that reactive oxygen species (ROSs) can activate NF-
B. Several lines of evidence indicate that TNF
mediates its intracellular signaling through ROSs.39 The direct evidence that TNF
can induce ROSs came from more recent studies showing H2O2 accumulation in TNF
-treated fibroblasts.40-42 To investigate whether TNF receptor signaling triggers ROS production in malignant T lymphocytes, we monitored the redox status using the oxidation-sensitive fluorescent dyes, DCFDA (for H2O2) and DHE (for ·O2) in J-Luc-
B cells treated with TNF
for different times. TNF
treatment resulted in production of ROSs in J-Luc-
B T cells. In contrast to the results previously found for fibroblasts, TNF
does not induce accumulation of H2O2 in Jurkat T cells. Instead, TNF
induces generation of the free radical ·O2 accompanied by reduction in endogenous H2O2 levels (Figure 2A). This observation indicates that TNF
can shift the cellular redox potential to a more oxidative state in Jurkat T cells.
|
B cells treated with different concentrations of wogonin. In contrast to TNF
, administration of wogonin resulted in a dose-dependent reduction in ·O2 levels accompanied by an increase in H2O2 levels (Figure 2B). Similar to Jurkat T cells, TNF
induces generation of ·O2 and simultaneously reduces the level of H2O2 in CEM T cells (Figure 2C). Thus, wogonin can shift the cellular redox equilibrium to a more reduced state, a reaction that mimics the function of the antiradical enzyme superoxide oxido reductase dismutase (SOD).
|
B cells were treated with TNF
in the presence or absence of wogonin. Interestingly, in the presence of wogonin, the TNF
-induced elevation of ·O2 is neutralized to almost normal levels in both CEM and Jurkat T cells (Figure 2C-D). These data demonstrate that wogonin can mimic SOD function to convert TNF
-induced ·O2 to the nonradical H2O2.
Wogonin attenuates TNF
-induced NF-
B activity
It is known that NF-
B can be activated by ROSs and that NF-
Bis a negative regulator of TNF
-induced cell death. To investigate whether blocking TNF
-induced ·O2 by wogonin leads to down-regulation of NF-
B activity, we monitored the NF-
B activity by measuring the luciferase activity of the TNF
-treated J-Luc-
B cells in the absence or presence of wogonin. The experiments showed that wogonin attenuated TNF
-induced NF-
B activity in a dose-dependent manner (Figure 3A). Further investigation of the molecular mechanisms showed that wogonin prevented phosphorylation of I
B by TNF
and thereby blocked TNF
-induced degradation of I
B (Figure 3B-C). These experiments demonstrate that wogonin sensitizes TNF
-induced apoptosis by down-regulation of NF-
B activity.
|
We observed that the levels of H2O2 were elevated in cells treated with wogonin. Normally, H2O2 is mostly degraded to H2O by glutathione (GSH) peroxidase and catalase. However, in the presence of transition metals H2O2 may give rise to a highly reactive hydroxyl radical (·OH) by the Fenton or the Haber-Weiss reaction.43 Therefore, elevation of H2O2 by wogonin might cause generation of ROSs and lead to apoptotic cell death. To investigate whether ROSs are involved in wogonin-induced apoptosis, cells were treated with wogonin in the presence or absence of the antioxidant N-acetyl-cysteine (NAC). Although wogonin can shift the redox status to produce more H2O2, NAC did not show any inhibitory effect on wogonin-induced cell death (Figure 4A, left). As a control, apoptosis induced by parthenolide, a compound that induces apoptosis via generation of ROSs,44 was blocked by NAC (Figure 4A, right). Also, no significant inhibitory effects of NAC were seen on wogonin/TNF
-induced apoptosis (Figure 4B). Thus, wogonin does not induce generation of ROSs to induce apoptosis.
Wogonin does not sensitize normal T cells to TNF
-induced apoptosis
In contrast to malignant T cells, wogonin does not sensitize freshly isolated peripheral blood T cells to TNF
-(Figure 5A) or TRAIL-induced apoptosis (Figure 5B). Freshly isolated (resting) T cells (day 0) are known to be resistant toward activation-induced cell death (AICD), whereas T cells activated for several days in culture become sensitive toward AICD.35 To investigate whether T cells at different activation stages have different susceptibilities to wogonin/TNF
or wogonin/TRAIL treatment, peripheral blood T cells activated by PHA overnight (day 1) or further cultured for 5 days in IL-2containing medium (day 6) were subjected to wogonin/TNF
or wogonin/TRAIL treatment. In all cases, no toxicity was seen in peripheral blood T cells. As control, wogonin elevated TNF
- and TRAIL-induced apoptosis in Jurkat cells (Figure 5). These results demonstrate that wogonin can selectively enhance TNF
- or TRAIL-induced apoptosis in malignant T cells.
Wogonin has a stronger effect on the redox status of malignant T cells
Increasing evidence shows that tumor cells have altered redox regulation and produce ROSs at elevated rates in vitro and in vivo.45 To further investigate the mechanism by which wogonin selectively enhances malignant but not normal T cells to TNF
-induced apoptosis, we first compared the redox status of malignant with that of normal T cells. In agreement with other studies,45 malignant Jurkat T cells produce significantly higher levels of the free radical ·O2 accompanied by much lower levels of H2O2 than that of normal T cells (Figure 6A). Wogonin also reduces the ·O2 levels and shifts the cellular redox equilibrium to a more reduced state in normal T cells (Figure 6B). However, wogonin shows stronger shifts of ·O2 to H2O2 in the malignant Jurkat than in normal T cells (Figure 6B). We next investigated the redox status of malignant and normal T cells after treatment with a combination of TNF
and wogonin. TNF
treatment induces elevation of ·O2 and a decrease of H2O2 in both malignant and normal T cells (Figure 6C). Again, wogonin shows much stronger shifts of ·O2 to H2O2 in the malignant than in normal T cells (Figure 6D-E). Thus, wogonin has stronger influence on the redox status in malignant than in normal T cells.
| Discussion |
|---|
|
|
|---|
shows broad cytotoxicity against a number of tumor cell lines, the clinical use of TNF
is limited because it induces a profound inflammatory response through activation of NF-
B. NF-
B also activates expression of various antiapoptotic genes that cause resistance to chemotherapy in many types of tumors.12-15,46 Thus, the decision between life and death in TNF
treatment is largely controlled by the activity of NF-
B. To overcome this problem, specific NF-
B inhibitors or drugs such as cycloheximide and actinomycin D, which block new protein synthesis, are usually used in combination with TNF
treatment to increase TNF
killing of tumor cells. However, these agents cause harmful side effects. Much effort has been devoted to search for agents that can specifically induce apoptosis in tumor cells, ideally with no or less toxicity to normal cells. Minimizing side effects and maximizing efficacy becomes a major goal in the development of apoptosis inducers. The principal active component of Huang-Qin, wogonin, has attracted our attention because it exerts cytotoxicity to several human cancer cell lines.30,31 In this study, we show that wogonin sensitizes TNF
-resistant malignant T cells toward TNF
-mediated apoptosis via attenuation of TNF
-induced NF-
B activity. Importantly, wogonin has no or little toxicity on peripheral blood mononuclear cells (Liu et al32 and our data). The wogonin-containing plant HuangQin is widely used in traditional Chinese medicine (TCM) to cure diseases associated with inflammation. Our data raise the potential to use wogonin as a sensitizer for TNF
anticancer therapy and to reduce the TNF
-induced inflammatory side effect.
|
|
|
mediates its intracellular signaling through reactive oxygen intermediates.39 Recently, several reports described that TNF
can directly induce accumulation of H2O2 in fibroblasts.40-42 In those studies, H2O2 production, beginning 2 hours after TNF
treatment, progressively accumulated up to 12 hours after TNF
treatment.42 In contrast to those studies, we show that TNF
rapidly (less than 60 minutes) induces elevation of the free radical ·O2 in Jurkat and CEM T cells and simultaneously reduces the cellular basal levels of H2O2. The highest level of ·O2 was readily detected 1 hour after administration of TNF
, and this level was maintained for at least 4 hours. Thus, TNF
can shift the cellular redox potential to a more oxidative state (Figure 2A). However, treatment of cells with TNF
alone has little effect on cell death due to NF-
B activation.
|
B activity and a synergistic increase in apoptotic cell death was seen in TNF
-treated malignant T-cell lines. Our data demonstrate that wogonin can promote TNF
-induced apoptosis via modulation of the cellular redox status. Interestingly, wogonin does not affect the redox status of normal T cells and therefore does not sensitize normal T cells to TNF
-induced apoptosis. In addition, the fact that wogonin suppresses TNF
-induced NF-
B activity indicates that it can reduce the proinflammatory side effects of TNF
.
Growing evidence indicates that ROSs can specifically activate certain intracellular signaling cascades and thus contribute to tumor development. It has been found that redox balance is impaired in cancer cells compared with normal cells.45 Human tumor cells have been shown to produce ROSs at a far greater rate than nontransformed cells.51,52 We also observed that Jurkat T cells produce much higher levels of the free radical ·O2 than normal T cells. In addition, increased expression or activity of the cellular antioxidant enzymes such as SOD, GSH peroxidase, catalase, peroxiredoxin, and malondialdehyde has been reported in tumor cell lines and tumor tissues.53 We show that wogonin can scavenge ·O2 in Jurkat and CEM tumor cells and shifts it to its breakdown product, H2O2, but has only a little effect on normal T cells. This may be explained by the fact that normal cells produce only very little ROSs and, therefore, only a small shift of redox status could be seen in normal T cells. In contrast, tumor cells produce abnormal higher levels of ROSs than normal cells and thus show strong influence by wogonin. This may explain why wogonin does not sensitize normal T cells to undergo TNF
-induced apoptosis.
Recently, it has been shown that TNF
may sensitize malignant cells to chemotherapeutic drugs in an NF-
Bindependent manner via the mitochondrial apoptosis pathway.54 As shown in this study, wogonin alone can trigger malignant cells to undergo apoptosis. Wogonin induces cell death mainly through the mitochondrial pathway (M.L.-W., unpublished data, May 2006). Therefore, TNF
might also sensitize malignant cells to wogonin through an NF-
Bindependent effect. Several studies indicate that TNF
-induced ROSs may promote TNF
-mediated cell death.41,42 In those studies, NF-
B activated by ROSs was demonstrated to up-regulate the antioxidant iron storage factor ferritin heavy chain, which in turn suppresses ROS accumulation and inhibits TNF
-induced apoptosis via prevention of ROS-induced sustained JNK activation.41 The role of ROSs in promoting TNF
-induced apoptosis was also demonstrated using NF-
Bdeficient cells in which H2O2 production, beginning 2 hours after TNF
treatment, progressively accumulated up to 12 hours after TNF
treatment.42 However, because H2O2 accumulation occurred relatively late (after several hours) in those studies, it has been queried whether H2O2 accumulation is a cause or rather an effect of cell death.6 In our studies, we show that TNF
directly induces production of ·O2. However, the TNF
-induced ROSs are not sufficient to induce cell death in malignant T cells.
In summary, we have shown that wogonin selectively sensitizes TNF
-induced apoptosis in malignant but not normal T cells. Wogonin is a potent antioxidant that can scavenge ROSs generated by TNF
treatment and can thereby down-regulate activation of NF-
B. Thus, wogonin enhances the cytotoxicity of TNF
on tumor cells and at the same time limits the proinflammatory effect of TNF
. In addition, wogonin significantly increases the toxicity of TRAIL to tumor cells. These data suggest that wogonin may serve as a TNF
or TRAIL adjuvant for cancer treatment.
| Authorship |
|---|
|
|
|---|
The authors declare no competing financial interests.
S.C.F., S.B., and J.Y.Z. contributed equally to this study.
| Acknowledgements |
|---|
This work was supported by the Deutsche Forschungsgemeinschaft, the Wilhelm Sander Stiftung, and the Tumor Center Heidelberg/Mannheim.
| Footnotes |
|---|
Prepublished online as Blood First Edition Paper, August 24, 2006; DOI 10.1182/blood-2006-03-011973.
An Inside Blood analysis of this article appears at the front of this issue.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.
Correspondence: M. Li-Weber, Tumor Immunology Program D030, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany; e-mail: m.li-weber{at}dkfz-heidelberg.de.
| References |
|---|
|
|
|---|
Related Article in Blood Online:
This article has been cited by other articles:
![]() |
G Kallifatidis, V Rausch, B Baumann, A Apel, B M Beckermann, A Groth, J Mattern, Z Li, A Kolb, G Moldenhauer, et al. Sulforaphane targets pancreatic tumour-initiating cells by NF-{kappa}B-induced antiapoptotic signalling Gut, July 1, 2009; 58(7): 949 - 963. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Lu, Q. Li, J. Li, F. Liu, and X. Yang Polysaccharide from Patrinia heterophylla Bunge Inhibits HeLa Cell Proliferation Through Induction of Apoptosis and Cell Cycle Arrest Lab Med, March 1, 2009; 40(3): 161 - 166. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Baumann, S. C. Fas, M. Giaisi, W. W. Muller, A. Merling, K. Gulow, L. Edler, P. H. Krammer, and M. Li-Weber Wogonin preferentially kills malignant lymphocytes and suppresses T-cell tumor growth by inducing PLC{gamma}1- and Ca2+-dependent apoptosis Blood, February 15, 2008; 111(4): 2354 - 2363. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Hasegawa, Y. Yamada, K. Komiyama, M. Hayashi, M. Ishibashi, T. Sunazuka, T. Izuhara, K. Sugahara, K. Tsuruda, M. Masuda, et al. A novel natural compound, a cycloanthranilylproline derivative (Fuligocandin B), sensitizes leukemia cells to apoptosis induced by tumor necrosis factor related apoptosis-inducing ligand (TRAIL) through 15-deoxy-{Delta}12, 14 prostaglandin J2 production Blood, September 1, 2007; 110(5): 1664 - 1674. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2006 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||